Oracle's Defining Quarter: A $638 Billion Backlog Collides With Regulatory Heat and a Cash Burn

Oracle reports Q1 FY2027 results Sept 10 amid record AI demand, $638B RPO, negative FCF, and rising debt. Analysts split on stock outlook.

Oracle enters its most consequential reporting window in years carrying a contradiction that has come to define its market profile: unprecedented demand for its AI infrastructure, and an equally unprecedented appetite for capital to feed it.

The company will publish fiscal first-quarter 2027 results on September 10 after the US market close, with a webcast conference call scheduled for 4 p.m. Central Time. The print arrives at a moment when the stock's trajectory has diverged sharply from its operational momentum — a gap that has split Wall Street between conviction buyers and cautious skeptics.

The Numbers That Frame the Debate

The headline figure dominating the pre-earnings conversation is the remaining performance obligation (RPO) of $638 billion, up 363 percent year over year. That backlog sits alongside cloud revenue growth of 39 percent to $34 billion in the last fiscal year, with the OCI infrastructure unit expanding 77 percent to $18.1 billion.

Analysts polled by CNBC expect revenue to climb 28 percent on a constant-currency basis in the upcoming quarter, with earnings per share up 18.5 percent. Longer-term projections from Barchart point to compound annual growth rates of 31 percent for revenue and 28 percent for earnings.

Yet the cost of that growth story is stark. Free cash flow came in at negative $23.7 billion for fiscal 2026, and net debt now stands at 4.5 times EBITDA. Reports indicate Oracle is planning an additional $40 billion in debt and equity raises to fund its infrastructure buildout — a financing burden that sets it apart from hyperscaler peers Amazon, Alphabet and Meta, which can largely self-fund their AI capex from operating cash flow.

A Stock That Has Priced in the Pain

The market's verdict on this trade-off has been severe. The shares closed Thursday at €130.90, up 4.0 percent on the day after finishing Wednesday at €125.82 — a bounce that does little to repair the year-to-date damage. The stock remains down roughly 21 percent since January, and sits about 57 percent below its 52-week high of €294.85 reached on September 10, 2025.

That recent advance has at least nudged the price back above near-term technical levels. The stock now trades 7.9 percent above its 50-day moving average of €121.27, though it remains roughly 14 percent under its 200-day average. The picture is one of stabilization on a lower plateau rather than a decisive reversal.

Brussels Adds a New Layer of Uncertainty

The earnings test arrives alongside fresh regulatory developments in Europe. Reuters reported that Oracle's licensing practices have drawn attention from EU competition authorities, though the European Commission has stressed that no formal investigation has been opened. Cloud licensing models have long been a friction point between Oracle and European regulators, and the prospect of more concrete steps is likely to keep investors on edge in the coming weeks.

Separately, media reports have circulated about a potential new round of layoffs at the company. Oracle has neither confirmed nor denied the reports, leaving shareholders guessing about the scale of cost reductions needed to support margin-intensive AI infrastructure growth. Reports elsewhere have put potential job cuts at 7,000 to 10,000 positions, with possible announcement dates of September 15 or 30. Headcount has already fallen from 162,000 to 141,000.

An older legal matter also continues to generate cash outflows: the $115 million settlement related to Oracle's advertising technologies is slated for payment beginning September 21, 2026, according to media reports. The case is resolved, but the timing adds another drain on capital discipline at a moment when investors are scrutinizing every dollar.

The Ellison Factor

Adding to the political dimension, CEO Larry Ellison faces scrutiny from the House Veterans' Affairs Committee over the electronic health records system for veterans. The project's budget has ballooned from an original $10 billion in 2018 to more than $27 billion, with estimated lifecycle costs of up to $50 billion. Representative Budzinski has voted in favor of subpoenaing Ellison, underscoring how Oracle's public-sector entanglements are drawing oversight while the company pours billions into AI data centers.

Wall Street's Divergent Views

The analyst community remains split on how to weigh the backlog against the balance sheet. TD Cowen cut its price target in early September from $300 to $240 while maintaining a Buy rating, citing concerns about AI data center expansion, elevated capital expenditures, debt levels, and the pace at which the order book converts into free cash flow.

On the other side of the ledger, a Bernstein analyst cited by UA.NEWS sees potential for the stock to double, arguing that the most aggressive phases of capital raising may be drawing to a close. That view aligns with Oracle's expanded partnership with HPE, which will supply networking equipment for Oracle's global AI data centers — a signal that the company is increasingly leaning on partners rather than pure self-financing.

The Core Question

For all the noise around regulation, layoffs and political scrutiny, the September 10 report will ultimately be judged on one question: whether Oracle can translate its record backlog into actual cash generation. The RPO figure is impressive in isolation, but its value depends on execution — and on a balance sheet that is already stretched thinner than most of its mega-cap technology peers.

The risks are well documented: heavy customer concentration, particularly the dependence on the OpenAI relationship, and leverage that exceeds what Amazon, Alphabet and Meta carry. The bull case rests on the substance of that $638 billion backlog and the possibility that the financing cycle is peaking.

Between now and the earnings call, Oracle remains what it has been for much of the past year: a high-risk growth story whose valuation arguably understates its operational momentum — but whose capital demands justify a healthy dose of caution. The September 10 print will determine which side of that equation wins out.